Central Hh Care, An Amedisys Company | |
2000 Riveredge Parkway Nw, Suite Gl200, Atlanta, Georgia 30328 | |
(770) 953-8570 | |
Name | Central Hh Care, An Amedisys Company |
---|---|
Location | 2000 Riveredge Parkway Nw, Suite Gl200, Atlanta, Georgia |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 117039 |
Ownership Type | Proprietary |
Service Area Zip Codes | 30004, 30005, 30008, 30009, 30022, 30024, 30060, 30062, 30064, 30066, 30067, 30068, 30069, 30075, 30076, 30080, 30082, 30101, 30114, 30126, 30144, 30152, 30236, 30238, 30260, 30274, 30288, 30294, 30296, 30297, 30305, 30306, 30308, 30309, 30313, 30318, 30319, 30324, 30326, 30327, 30328, 30329, 30339, 30342, 30349, 30350, 30354, 30548 |
NPI Number | 1831147529 |
Organization Name | AMEDISYS GEORGIA LLC |
Doing Business As | CENTRAL HOME HEALTH CARE, AN AMEDISYS COMPANY |
Address | 2000 Riveredge Pkwy Nw, Suite Gl200, Atlanta, GA 30328 |
Phone Number | 770-953-8570 |
News Archive
Research on the gut microbiome is one of the most promising areas of science today. In a new special issue of Clinical Gastroenterology and Hepatology, the American Gastroenterological Association has taken the deep-dive into the gut microbiome that both scientists and the public are looking for to help them better understand the effects of the microbiome on health and disease.
Researchers have found a new biomarker for cyanide poisoning, which may extend its detection window in death investigations by weeks if not months.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).
Non-Invasive Monitoring Systems, Inc. announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled "Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction," relates to the comprehensively researched technology underlying NIMS' Exer-Rest acceleration therapeutic platform.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 7 days ago
Quality Rating: |
News Archive
Research on the gut microbiome is one of the most promising areas of science today. In a new special issue of Clinical Gastroenterology and Hepatology, the American Gastroenterological Association has taken the deep-dive into the gut microbiome that both scientists and the public are looking for to help them better understand the effects of the microbiome on health and disease.
Researchers have found a new biomarker for cyanide poisoning, which may extend its detection window in death investigations by weeks if not months.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).
Non-Invasive Monitoring Systems, Inc. announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled "Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction," relates to the comprehensively researched technology underlying NIMS' Exer-Rest acceleration therapeutic platform.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 7 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 97.9 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 99.9 | 98.6 |
How often the home health team checked patients’ risk of falling | 99.1 | 99.6 |
How often the home health team checked patients for depression | 90.9 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 81.8 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 86.9 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 94.8 | 96.4 |
News Archive
Research on the gut microbiome is one of the most promising areas of science today. In a new special issue of Clinical Gastroenterology and Hepatology, the American Gastroenterological Association has taken the deep-dive into the gut microbiome that both scientists and the public are looking for to help them better understand the effects of the microbiome on health and disease.
Researchers have found a new biomarker for cyanide poisoning, which may extend its detection window in death investigations by weeks if not months.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).
Non-Invasive Monitoring Systems, Inc. announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled "Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction," relates to the comprehensively researched technology underlying NIMS' Exer-Rest acceleration therapeutic platform.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 7 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 76.1 | 79.6 |
How often patients got better at getting in and out of bed | 77.5 | 81.1 |
How often patients got better at bathing | 80 | 82.3 |
How often patients’ breathing improved | 82.8 | 82.8 |
How often patients’ wounds improved or healed after an operation | 94 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 68 | 75 |
How often home health patients had to be admitted to the hospital | 16.7 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 12.9 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 95.6 | 94 |
News Archive
Research on the gut microbiome is one of the most promising areas of science today. In a new special issue of Clinical Gastroenterology and Hepatology, the American Gastroenterological Association has taken the deep-dive into the gut microbiome that both scientists and the public are looking for to help them better understand the effects of the microbiome on health and disease.
Researchers have found a new biomarker for cyanide poisoning, which may extend its detection window in death investigations by weeks if not months.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).
Non-Invasive Monitoring Systems, Inc. announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled "Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction," relates to the comprehensively researched technology underlying NIMS' Exer-Rest acceleration therapeutic platform.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 7 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
Research on the gut microbiome is one of the most promising areas of science today. In a new special issue of Clinical Gastroenterology and Hepatology, the American Gastroenterological Association has taken the deep-dive into the gut microbiome that both scientists and the public are looking for to help them better understand the effects of the microbiome on health and disease.
Researchers have found a new biomarker for cyanide poisoning, which may extend its detection window in death investigations by weeks if not months.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).
Non-Invasive Monitoring Systems, Inc. announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled "Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction," relates to the comprehensively researched technology underlying NIMS' Exer-Rest acceleration therapeutic platform.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 7 days ago
The patient survey data of Central Hh Care, An Amedisys Company is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 82 | 88 |
Percent of patients who reported that their home health team communicated well with them | 77 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 73 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 76 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 66 | 78 |
News Archive
Research on the gut microbiome is one of the most promising areas of science today. In a new special issue of Clinical Gastroenterology and Hepatology, the American Gastroenterological Association has taken the deep-dive into the gut microbiome that both scientists and the public are looking for to help them better understand the effects of the microbiome on health and disease.
Researchers have found a new biomarker for cyanide poisoning, which may extend its detection window in death investigations by weeks if not months.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).
Non-Invasive Monitoring Systems, Inc. announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled "Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction," relates to the comprehensively researched technology underlying NIMS' Exer-Rest acceleration therapeutic platform.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 7 days ago
Visiting Nurse Health System Location: 5775 Glenridge Drive, Ne, Suite E200, Atlanta, Georgia 30328 Ratings: Phone: (404) 215-6092 | |
Central Hh Care, An Amedisys Company Location: 2000 Riveredge Parkway Nw, Suite Gl200, Atlanta, Georgia 30328 Ratings: Phone: (770) 953-8570 | |
Interim Healthcare Of Atlanta Inc Location: 5555 Glenridge Connector, Suite 750, Atlanta, Georgia 30342 Ratings: Phone: (404) 843-2708 | |
Georgia Home Health Location: 2000 Riveredge Parkway Suite 925, Atlanta, Georgia 30328 Ratings: Phone: (770) 688-1000 | |
Kindred At Home Location: 1303 Hightower Trail, Suite 105, Atlanta, Georgia 30350 Ratings: Phone: (770) 998-1393 | |
Encompass Health Home Health Location: 5887 Glenridge Dr, Suite 130, Atlanta, Georgia 30328 Ratings: Phone: (678) 732-3470 |